Treatment with beta‐adrenoceptor blockers reduces plasma melatonin concentration.

Cowen, Philip J.; Bevan, John S.; Gosden, Barbara; Elliott, Sarah A.

doi:10.1111/j.1365-2125.1985.tb02640.x

Cited by 64 publications

(30 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cowen et al 10 have shown that patients treated for arterial hypertension with b-adrenolytics had lower concentrations of melatonin than did patients who were receiving diuretics. All our patients were receiving medicines from this group, hence they can be regarded as comparable in this respect.…”

Section: Discussionmentioning

confidence: 99%

Melatonin for nondippers with coronary artery disease: assessment of blood pressure profile and heart rate variability

et al. 2009

View full text Add to dashboard Cite

The aim of this study was to assess the effects of 5 mg melatonin before sleep in patients with coronary artery disease (CAD) and with an abnormal circadian pattern of blood pressure (BP) on changes in circadian BP profile and heart rate variability (HRV). Sixty patients with CAD, nondippers aged 48-80 years (male 75%), were included. In addition to previous treatment, they were randomly allocated to melatonin or placebo. After 90 days, a second 24-h BP monitoring was carried out. Each patient had two sessions (before randomization and at the end of study) of 24-h ECG monitoring to assess the changes in HRV. Inclusion of melatonin led to BP pattern normalization in 35% of patients in the melatonin group and in 15% of controls (P¼0.609). This effect was reached not only by a decrease in nighttime BP, but also by an increase in daytime BP (significant in the melatonin group). A nonoptimal effect for BP profile was observed in 12.5% of patients: extreme-or reverse dippers. In patients with conversion from nondippers to dippers (responders), an increase in standard deviation of normal-to-normal intervals between initial and final HRV analyses was observed. Nonresponders represented an increase in the mean circadian heart rate. To avoid nonoptimal effects, the inclusion of melatonin in pharmacotherapy of patients with CAD should be based on monitoring of circadian BP profile, before and during treatment. As melatonin caused not only a nocturnal decrease in BP but also a daytime increase, it should not be recommended in patients with 'high normal' values of BP because of the danger of induction of arterial hypertension.

show abstract

Section: Discussionmentioning

confidence: 99%

Melatonin for nondippers with coronary artery disease: assessment of blood pressure profile and heart rate variability

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The mean daily level of pineal HIOMT activity is about 4.3 Ϯ 0.1 nmol/h/mg protein in human (Bernard et al, 1995) and about 9 nmol/h/mg protein in rhesus monkey with no significant day/night variation. Daytime ␤ 1 -AR stimulation does not stimulate MEL synthesis (Berlin et al, 1995), but its nocturnal synthesis can be inhibited by a ␤ 1 -AR antagonist (Cowen et al, 1985). In humans, there is a large interindividual variability in the daily pattern of MEL synthesis, which also varies depending on age (Baskett et al, 2001).…”

Section: Multiple Regulation Of Pineal Melatonin Synthesis In Mammalsmentioning

confidence: 99%

Generation of the Melatonin Endocrine Message in Mammals: A Review of the Complex Regulation of Melatonin Synthesis by Norepinephrine, Peptides, and Other Pineal Transmitters

2003

View full text Add to dashboard Cite

“…-adrenoceptor maintenance insomniacs, insomniacs with a history of sleep antagonists and antiflammatory agents (Cowen et al 1985; onset insomnia were also excluded from the study. That is we Brismar et al 1988;Myers and Badia 1993;Murphy et al excluded insomniacs with a mean SOL > 30 min.…”

Section: Introductionmentioning

confidence: 99%

“…Cowen et al 1985; Brismar et al 1988; Research Council grant number 950082. Myers and Badia 1993; Murphy et al 1996;van den Heuvel et al 1997).…”

mentioning

confidence: 99%

6‐Sulfatoxymelatonin excretion and self‐reported sleep in good sleeping controls and 55–80‐year‐old insomniacs

Lushington¹,

Lack

Kennaway³

et al. 1998

Journal of Sleep Research

View full text Add to dashboard Cite

The pineal hormone melatonin is thought to play a role in sleep initiation and maintenance. This was examined in a large sample of good sleeping controls ( n=52) and sleep maintenance insomniacs (n=56), aged 55–80 y. Subjects collected 5 d of self‐reported sleep diary measures, and 12‐h urine samples (08.00–20.00 and 20.00–08.00 h) for analysis of the urinary melatonin metabolite, 6‐sulphatoxymelatonin (aMT.6S). Insomniacs reported a significantly greater amount of wake after sleep onset, less sleep in total, less efficient sleep and poorer quality sleep compared to controls. However, no significant differences in melatonin excretion were observed between controls and insomniacs, with both groups showing similar mean (SEM) 12‐h night‐time [30.9 (2.9) vs. 30.6 (3.3) nmoles, respectively] as well as 24‐h total [38.7 (3.4) vs. 36.7 (3.8)] aMT.6S excretion levels. No significant correlations were observed with any sleep parameters nor any effects of medication (anti‐inflammatory agents, hormone replacement therapy, and an undifferentiated group of medications). The present results do not support a simple relationship between total melatonin production and self‐reported sleep quality and duration in the aged.

show abstract

Treatment with beta‐adrenoceptor blockers reduces plasma melatonin concentration.

Cited by 64 publications

References 8 publications

Melatonin for nondippers with coronary artery disease: assessment of blood pressure profile and heart rate variability

Melatonin for nondippers with coronary artery disease: assessment of blood pressure profile and heart rate variability

Generation of the Melatonin Endocrine Message in Mammals: A Review of the Complex Regulation of Melatonin Synthesis by Norepinephrine, Peptides, and Other Pineal Transmitters

6‐Sulfatoxymelatonin excretion and self‐reported sleep in good sleeping controls and 55–80‐year‐old insomniacs

Contact Info

Product

Resources

About